Jin Medical International Ltd. — FY2023 Form 20-F
Reporting period: Fiscal year ended September 30, 2023. This is an annual report, not a standalone fourth-quarter filing; the text does not provide separate Q4 results. Financial statements are prepared under U.S. GAAP.
Business context
The company designs and manufactures wheelchairs and living-aid products in China through a variable interest entity (VIE) and its subsidiaries. It does not own equity in the VIE; it relies on contractual arrangements to control and consolidate it for accounting purposes. Japan is its largest market, and manual wheelchairs dominate sales.
Key financial metrics
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $19.82 million | $19.19 million |
| Gross profit | $6.78 million | $6.20 million |
| Gross margin | 34.2% | 32.3% |
| Operating income | $2.87 million | $2.13 million |
| Net income | $2.88 million | $2.71 million |
| Net cash from operating activities | $3.11 million | $1.58 million |
| Cash at year-end | $6.93 million | $4.79 million |
| Short-term investments at year-end | $9.77 million | $2.28 million |
| Current assets / current liabilities | $31.12 million / $8.92 million | $18.90 million / $5.70 million |
| Short-term bank debt | $4.11 million | None reported |
The company reported no off-balance-sheet arrangements. FY2023 investing cash outflow was $7.73 million, primarily reflecting purchases of short-term investments; financing cash inflow was $6.91 million, including IPO proceeds and bank borrowing. The outstanding bank loan was due September 2024, at a fixed 2.90% rate.
Changes versus the prior year
- Revenue increased 3.3% in U.S. dollars; management said revenue grew 11.2% excluding foreign-currency translation effects. RMB depreciation partly offset the operating recovery.
- Gross profit increased 9.5% and gross margin rose 1.9 percentage points, attributed to higher production volumes and product mix, including higher-margin new living-aid products.
- Operating expenses decreased 3.7%, as lower R&D spending more than offset higher selling and administrative expenses. Net income rose 6.3%.
- Operating cash flow improved, but cash was also affected by working-capital movements, including inventory and payables changes.
- The company completed its Nasdaq IPO in March 2023, raising approximately $6.36 million net of stated offering expenses. A 20-for-1 forward share split became effective in February 2024; share and per-share data were retrospectively adjusted.
Outlook, risks and unusual items
- Outlook: No quantified earnings or revenue guidance is provided. Management plans to invest in R&D, broaden electric-wheelchair and living-aid offerings, expand distribution and pursue international markets. The new products were still being tested with selected customers.
- Customer concentration: Nissin represented 69.8% of FY2023 sales; Nissin and its subsidiaries together represented 78.2%. The annually renewing framework contract does not require minimum purchases.
- VIE and China exposure: The contractual control structure has not been tested in court and could be challenged or restricted by PRC authorities. Foreign-exchange controls and statutory reserve requirements may limit transfers of cash and profits from China.
- Related parties: Year-end amounts due from related parties were $4.24 million, including a $4.11 million advance to a CEO-controlled entity that the filing says was collected in October 2023. Investors should assess the purpose, approval and repayment evidence for these transactions.
- Controls and auditor: Management concluded disclosure controls were ineffective and identified material weaknesses, including insufficient U.S. GAAP/SEC reporting expertise and inadequate formal closing controls. No auditor attestation on internal controls was included. DNTW Toronto LLP resigned in February 2024 after an unresolved disagreement over audit scope and did not issue an opinion on FY2023 statements; Audit Alliance LLP subsequently audited the statements and issued an unqualified opinion.
- Listing: Nasdaq had raised public-holder and annual-report filing deficiencies. The hearing panel granted continued listing subject to filing the FY2023 Form 20-F by May 20, 2024; the report is dated April 26, 2024. Verify the company’s subsequent listing status and compliance.
- Other risks and contingencies: Raw-material costs, currency movements, supply-chain disruption, product liability and medical-device regulation pose risks. The company reports no material legal proceedings. It generally does not carry product-liability insurance in its two largest markets, Japan and China. It also does not expect to pay dividends in the foreseeable future.
Most important facts for investors to verify
- Whether Nissin’s purchases and the customer relationship remain stable, and how the company is reducing dependence on this channel.
- Evidence of collection of the $4.11 million related-party advance and the governance controls over related-party balances and sales.
- Progress in remediating internal-control weaknesses, and the current auditor’s status and any further audit-scope or reporting issues.
- Nasdaq continued-listing compliance and any subsequent regulatory filings or notices.
- Liquidity quality: the terms, maturity and risk profile of short-term investments, availability of PRC-held cash for offshore needs, and repayment or renewal of bank debt.
- Whether new products gain meaningful commercial traction while maintaining margins and meeting applicable safety and certification requirements.